Previous article Next article

The Australian Competition Authority does not oppose an acquisition of a major manufacturer of animal health products and drugs subject to a divestiture (Zoetis / Jurox)

Zoetis' proposed acquisition of Jurox not opposed, subject to divestiture* The ACCC will not oppose the proposed acquisition of Jurox by Zoetis after accepting a court-enforceable undertaking from Zoetis to divest Jurox’s intramammary product range, consisting of intramammary antibiotics for dry and lactating cows and teat sealants for cows. Zoetis and Jurox develop, manufacture and sell animal health products. They are two of the leading suppliers in Australia of teat sealants and intramammary antibiotics for lactating and dry cows, which are products used to treat or prevent bacterial

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Australian Competition Authority, The Australian Competition Authority does not oppose an acquisition of a major manufacturer of animal health products and drugs subject to a divestiture (Zoetis / Jurox), 15 September 2022, e-Competitions Preview, Art. N° 108741

Visites 29

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues